Pefloxacin Mesylate

Pefloxacin mesylate: description, use and features

Pefloxacin mesylate is an antimicrobial drug from the fluoroquinolone group. It is widely used to combat infectious diseases and is produced in Russia. In this article we will look at the main characteristics of pefloxacin mesylate, its use, contraindications, side effects, interactions with other drugs and some features of use.

Pefloxacin mesylate is produced by the State Scientific Center for Antibiotics in Russia. Its international name is pefloxacin. The drug is also known under various synonyms, such as Abaktal, Pelox-400, Perti, Perflox, Peflacin, Peflobid, Pefloxafer, Pefloxacin, Pefloxacin methane sulfonate dihydrate, Pefloxacin-AKOS, Pefloxacin mesilate and Unikpef. The dosage form of pefloxacin mesylate is film-coated tablets containing 200 mg of the active substance, pefloxacin.

Pefloxacin mesylate is used to treat various infections of the upper and lower respiratory tract, urinary and gastrointestinal tracts, skin and soft tissues. It is effective for diseases such as salmonellosis, typhoid fever, epididymitis, otitis media, prostatitis, gonorrhea, chancroid, pelvic inflammatory diseases in women, cholecystitis, cholangitis, gallbladder empyema, intra-abdominal abscesses, peritonitis, septicemia, infective endocarditis, meningitis , osteomyelitis and infectious arthritis. Pefloxacin mesylate can also be used to prevent surgical infections.

Pefloxacin mesylate has some contraindications. It is not recommended for hypersensitivity to the drug, hemolytic anemia associated with glucose-6-phosphate dehydrogenase deficiency, cerebral atherosclerosis, epilepsy, impaired liver and kidney function, pregnancy, breastfeeding and in children under 15 years of age.

Pefloxacin mesylate may cause some side effects, including nausea, vomiting, diarrhea, abdominal pain, myalgia, arthralgia, tendonitis, headaches. Update on Pfizer COVID-19 vaccine and its effectiveness against new strains

The Pfizer-BioNTech COVID-19 vaccine (also known as BNT162b2 or Comirnaty) was developed to prevent COVID-19 infection. The vaccine is based on mRNA technology, which trains the immune system to recognize and fight the SARS-CoV-2 virus.

As of my knowledge in September 2021, the Pfizer-BioNTech vaccine has been approved for use in many countries, including the US, European Union, UK and others. It has undergone thorough clinical trials, which have shown its high effectiveness and safety.

Initial clinical studies showed that the Pfizer-BioNTech vaccine has a high level of effectiveness against the original strain of the SARS-CoV-2 virus. The vaccine was more than 90% effective in preventing COVID-19 disease in vaccinated people.

However, over time, new variants of the virus have emerged, including so-called “variants of concern” or “variants of interest.” These variants have some mutations in their genome that may affect their spread and the effectiveness of vaccines.

Some studies have shown that the Pfizer-BioNTech vaccine remains highly effective against some of these new variants. For example, the vaccine was effective against the B.1.1.7 variant (also known as the "UK variant") and B.1.351 (also known as the "South African variant"), but with some reduction in effectiveness compared to the original strain.

Vaccine makers Pfizer-BioNTech and other researchers continue to study the vaccine's effectiveness against new variants of the virus, such as the delta variant (B.1.617.2). Initial data indicates that the vaccine still provides protection against severe disease and hospitalizations caused by the delta variant, but there may be some reduction in effectiveness in preventing mild disease and infection.

It is important to note that vaccination remains one of the most effective ways to combat COVID-19 and related complications. Regular update and development of vaccines is an active area of ​​research, and vaccine manufacturers are looking to adapt them to new virus variants to ensure the best possible outcome.